FusionNeoAntigen Logo

Home

Download

Statistics

Examples

Help

Contact

Terms of Use

Center for Computational Systems Medicine
leaf

Fusion Gene and Fusion Protein Summary

leaf

Fusion Amino Acid Sequences (multiple BPs and multiple gene isoforms)

leaf

Fusion Protein Breakpoint Sequences - (for the Screening of the FusionNeoAntigens)

leaf

Potential FusionNeoAntigens in HLA I - (netMHCpan v4.1 + deepHLApan v1.1)

leaf

Potential FusionNeoAntigens in HLA II - (netMHCIIpan v4.1)

leaf

Fusion Breakpoint 14 AA Peptide Structure - (RoseTTAFold)

leaf

Filtering FusionNeoAntigens Through Checking the Interaction with HLAs in 3D - (Glide)

leaf

Vaccine Design for the FusionNeoAntigens (RNA/protein sequences)

leaf

Potential target of CAR-T therapy development

leaf

Information on the samples that have these potential fusion neoantigens

leaf

Fusion Protein Targeting Drugs - (Manual Curation)

leaf

Fusion Protein Related diseases - (Manual Curation)

Fusion Protein:AFF3-HDAC5

Fusion Gene and Fusion Protein Summary

check button Fusion gene summary
Fusion partner gene informationFusion gene name: AFF3-HDAC5
FusionPDB ID: 2685
FusionGDB2.0 ID: 2685
HgeneTgene
Gene symbol

AFF3

HDAC5

Gene ID

3899

10014

Gene nameAF4/FMR2 family member 3histone deacetylase 5
SynonymsLAF4|MLLT2-likeHD5|NY-CO-9
Cytomap

2q11.2

17q21.31

Type of geneprotein-codingprotein-coding
DescriptionAF4/FMR2 family member 3MLLT2-related proteinlymphoid nuclear protein 4lymphoid nuclear protein related to AF4protein LAF-4histone deacetylase 5antigen NY-CO-9
Modification date2020031320200313
UniProtAcc

P51826

Main function of 5'-partner protein: FUNCTION: Putative transcription activator that may function in lymphoid development and oncogenesis. Binds, in vitro, to double-stranded DNA.

Q9UQL6

Main function of 5'-partner protein: FUNCTION: Responsible for the deacetylation of lysine residues on the N-terminal part of the core histones (H2A, H2B, H3 and H4). Histone deacetylation gives a tag for epigenetic repression and plays an important role in transcriptional regulation, cell cycle progression and developmental events. Histone deacetylases act via the formation of large multiprotein complexes. Involved in muscle maturation by repressing transcription of myocyte enhancer MEF2C. During muscle differentiation, it shuttles into the cytoplasm, allowing the expression of myocyte enhancer factors. Involved in the MTA1-mediated epigenetic regulation of ESR1 expression in breast cancer. Serves as a corepressor of RARA and causes its deacetylation (PubMed:28167758). In association with RARA, plays a role in the repression of microRNA-10a and thereby in the inflammatory response (PubMed:28167758). {ECO:0000269|PubMed:24413532, ECO:0000269|PubMed:28167758}.
Ensembl transtripts involved in fusion geneENST idsENST00000317233, ENST00000356421, 
ENST00000409236, ENST00000409579, 
ENST00000483600, 
ENST00000225983, 
ENST00000336057, ENST00000393622, 
ENST00000586802, 
Fusion gene scores for assessment (based on all fusion genes of FusionGDB 2.0)* DoF score17 X 13 X 7=154713 X 11 X 8=1144
# samples 1714
** MAII scorelog2(17/1547*10)=-3.18586654531133
possibly effective Gene in Pan-Cancer Fusion Genes (peGinPCFGs).
DoF>8 and MAII<0
log2(14/1144*10)=-3.03058831983342
possibly effective Gene in Pan-Cancer Fusion Genes (peGinPCFGs).
DoF>8 and MAII<0
Fusion gene context

PubMed: AFF3 [Title/Abstract] AND HDAC5 [Title/Abstract] AND fusion [Title/Abstract]

Fusion neoantigen context

PubMed: AFF3 [Title/Abstract] AND HDAC5 [Title/Abstract] AND neoantigen [Title/Abstract]

Most frequent breakpoint (based on all fusion genes of FusionGDB 2.0)AFF3(100623094)-HDAC5(42195072), # samples:1
AFF3(100623094)-HDAC5(42171202), # samples:1
Anticipated loss of major functional domain due to fusion event.AFF3-HDAC5 seems lost the major protein functional domain in Hgene partner, which is a CGC by not retaining the major functional domain in the partially deleted in-frame ORF.
AFF3-HDAC5 seems lost the major protein functional domain in Hgene partner, which is a CGC by not retaining the major functional domain in the partially deleted in-frame ORF.
AFF3-HDAC5 seems lost the major protein functional domain in Hgene partner, which is a essential gene by not retaining the major functional domain in the partially deleted in-frame ORF.
AFF3-HDAC5 seems lost the major protein functional domain in Hgene partner, which is a essential gene by not retaining the major functional domain in the partially deleted in-frame ORF.
AFF3-HDAC5 seems lost the major protein functional domain in Hgene partner, which is a CGC due to the frame-shifted ORF.
AFF3-HDAC5 seems lost the major protein functional domain in Hgene partner, which is a essential gene due to the frame-shifted ORF.
AFF3-HDAC5 seems lost the major protein functional domain in Tgene partner, which is a epigenetic factor due to the frame-shifted ORF.
AFF3-HDAC5 seems lost the major protein functional domain in Tgene partner, which is a IUPHAR drug target due to the frame-shifted ORF.
* DoF score (Degree of Frequency) = # partners X # break points X # cancer types
** MAII score (Major Active Isofusion Index) = log2(# samples/DoF score*10)

check button Gene ontology of each fusion partner gene with evidence of Inferred from Direct Assay (IDA) from Entrez
PartnerGeneGO IDGO termPubMed ID
TgeneHDAC5

GO:0000122

negative regulation of transcription by RNA polymerase II

16236793

TgeneHDAC5

GO:0016575

histone deacetylation

10869435



check button Four levels of functional features of fusion genes
Go to FGviewer search page for the most frequent breakpoint (https://ccsmweb.uth.edu/FGviewer/chr2:100623094/chr17:42195072)
- FGviewer provides the online visualization of the retention search of the protein functional features across DNA, RNA, protein, and pathological levels.
- How to search
1. Put your fusion gene symbol.
2. Press the tab key until there will be shown the breakpoint information filled.
4. Go down and press 'Search' tab twice.
4. Go down to have the hyperlink of the search result.
5. Click the hyperlink.
6. See the FGviewer result for your fusion gene.
FGviewer

check buttonRetention analysis results of each fusion partner protein across 39 protein features of UniProt such as six molecule processing features, 13 region features, four site features, six amino acid modification features, two natural variation features, five experimental info features, and 3 secondary structure features, are available here.

check buttonFusion gene breakpoints across AFF3 (5'-gene)
* Click on the image to open the UCSC genome browser with custom track showing this image in a new window.
all structure

check buttonFusion gene breakpoints across HDAC5 (3'-gene)
* Click on the image to open the UCSC genome browser with custom track showing this image in a new window.
all structure


Top

Fusion Amino Acid Sequences


check buttonFusion information from ORFfinder translation from full-length transcript sequence from FusionPDB.
HenstTenstHgeneHchrHbpHstrandTgeneTchrTbpTstrandSeq length
(transcript)
BP loci
(transcript)
Predicted start
(transcript)
Predicted stop
(transcript)
Seq length
(amino acids)
ENST00000409236AFF3chr2100623094-ENST00000225983HDAC5chr1742171202-589198689242601122
ENST00000409236AFF3chr2100623094-ENST00000393622HDAC5chr1742171202-588498689242601122
ENST00000409236AFF3chr2100623094-ENST00000336057HDAC5chr1742171202-562898689240051037
ENST00000409236AFF3chr2100623094-ENST00000586802HDAC5chr1742171202-434398689242601122

check buttonDeepORF prediction of the coding potential based on the fusion transcript sequence of in-frame fusion genes. DeepORF is a coding potential classifier based on convolutional neural network by comparing the real Ribo-seq data. If the no-coding score < 0.5 and coding score > 0.5, then the in-frame fusion transcript is predicted as being likely translated.
HenstTenstHgeneHchrHbpHstrandTgeneTchrTbpTstrandNo-coding scoreCoding score
ENST00000409236ENST00000225983AFF3chr2100623094-HDAC5chr1742171202-0.0121211750.98787886
ENST00000409236ENST00000393622AFF3chr2100623094-HDAC5chr1742171202-0.0122917990.9877082
ENST00000409236ENST00000336057AFF3chr2100623094-HDAC5chr1742171202-0.0153475480.98465246
ENST00000409236ENST00000586802AFF3chr2100623094-HDAC5chr1742171202-0.0236526320.9763474

check button Predicted full-length fusion amino acid sequences. For individual full-length fusion transcript sequence from FusionPDB, we ran ORFfinder and chose the longest ORF among all the predicted ones.

Get the fusion protein sequences from here.

Fusion protein sequence information is available in the fasta format.
>FusionGDB ID_FusionGDB isoform ID_FGname_Hgene_Hchr_Hbp_Henst_Tgene_Tchr_Tbp_Tenst_length(fusion AA) seq_BP

Top

Fusion Protein Breakpoint Sequences for AFF3-HDAC5

check button +/-13 AA sequence from the breakpoints of the fusion protein sequences.
HgeneHchrHbpTgeneTchrTbpLength(fusion protein)BP in fusion proteinPeptide
AFF3chr2100623094HDAC5chr174217120298631GQALQVQHPQAGGVEVKPVLPRAMPS

Top

Potential FusionNeoAntigen Information of AFF3-HDAC5 in HLA I

check button Multiple sequence alignments of the potential FusionNeoAntigens per fusion breakpoints. If the MSA is empty, then it means that there were predicted fusion neoantigens in this fusion breakpoint, but those predicted fusion neoantigens were not across the breakpoint, which is not fusion-specific.
AFF3-HDAC5_100623094_42171202.msa

check button Potential FusionNeoAntigen Information
* We used NetMHCpan v4.1 (%rank<0.5) and deepHLApan v1.1 (immunogenic score>0.5)
Fusion geneHchrHbpTgeneTchrTbpHLA IFusionNeoAntigen peptideBinding scoreImmunogenic scoreNeoantigen start (at BP 13)Neoantigen end (at BP 13)
AFF3-HDAC5chr2100623094chr1742171202986HLA-B56:01HPQAGGVEV0.99320.7068716
AFF3-HDAC5chr2100623094chr1742171202986HLA-B55:01HPQAGGVEV0.97260.5303716
AFF3-HDAC5chr2100623094chr1742171202986HLA-B35:03HPQAGGVEV0.96920.8163716
AFF3-HDAC5chr2100623094chr1742171202986HLA-B51:02HPQAGGVEV0.96890.795716
AFF3-HDAC5chr2100623094chr1742171202986HLA-B35:01HPQAGGVEV0.94820.8365716
AFF3-HDAC5chr2100623094chr1742171202986HLA-B35:04HPQAGGVEV0.94510.9594716
AFF3-HDAC5chr2100623094chr1742171202986HLA-B35:02HPQAGGVEV0.94510.9594716
AFF3-HDAC5chr2100623094chr1742171202986HLA-B35:08HPQAGGVEV0.92710.7639716
AFF3-HDAC5chr2100623094chr1742171202986HLA-B51:01HPQAGGVEV0.89670.775716
AFF3-HDAC5chr2100623094chr1742171202986HLA-B35:05HPQAGGVEV0.86880.6365716
AFF3-HDAC5chr2100623094chr1742171202986HLA-B13:02VQHPQAGGV0.67680.9165514
AFF3-HDAC5chr2100623094chr1742171202986HLA-B08:09HPQAGGVEV0.59290.7859716
AFF3-HDAC5chr2100623094chr1742171202986HLA-B81:01HPQAGGVEV0.41070.7505716
AFF3-HDAC5chr2100623094chr1742171202986HLA-B82:01HPQAGGVEV0.22040.7893716
AFF3-HDAC5chr2100623094chr1742171202986HLA-B52:01VQHPQAGGV0.0710.989514
AFF3-HDAC5chr2100623094chr1742171202986HLA-B38:02QHPQAGGVEV0.97990.9852616
AFF3-HDAC5chr2100623094chr1742171202986HLA-B13:02VQHPQAGGVEV0.98480.9278516
AFF3-HDAC5chr2100623094chr1742171202986HLA-B54:01HPQAGGVEV0.99310.8477716
AFF3-HDAC5chr2100623094chr1742171202986HLA-B56:04HPQAGGVEV0.97360.8167716
AFF3-HDAC5chr2100623094chr1742171202986HLA-B35:12HPQAGGVEV0.94510.9594716
AFF3-HDAC5chr2100623094chr1742171202986HLA-B78:01HPQAGGVEV0.9210.865716
AFF3-HDAC5chr2100623094chr1742171202986HLA-B51:08HPQAGGVEV0.83510.5381716
AFF3-HDAC5chr2100623094chr1742171202986HLA-B42:02HPQAGGVEV0.81040.6493716
AFF3-HDAC5chr2100623094chr1742171202986HLA-B42:01HPQAGGVEV0.75610.6366716
AFF3-HDAC5chr2100623094chr1742171202986HLA-B39:10HPQAGGVEV0.64750.9487716
AFF3-HDAC5chr2100623094chr1742171202986HLA-B39:09QHPQAGGVEV0.98470.8964616
AFF3-HDAC5chr2100623094chr1742171202986HLA-B39:05QHPQAGGVEV0.9740.9386616
AFF3-HDAC5chr2100623094chr1742171202986HLA-B55:02HPQAGGVEV0.97990.6972716
AFF3-HDAC5chr2100623094chr1742171202986HLA-B35:22HPQAGGVEV0.9760.7744716
AFF3-HDAC5chr2100623094chr1742171202986HLA-B59:01HPQAGGVEV0.97530.7772716
AFF3-HDAC5chr2100623094chr1742171202986HLA-B56:02HPQAGGVEV0.97360.8167716
AFF3-HDAC5chr2100623094chr1742171202986HLA-B35:13HPQAGGVEV0.96790.8257716
AFF3-HDAC5chr2100623094chr1742171202986HLA-B56:05HPQAGGVEV0.95720.7473716
AFF3-HDAC5chr2100623094chr1742171202986HLA-B35:77HPQAGGVEV0.94820.8365716
AFF3-HDAC5chr2100623094chr1742171202986HLA-B35:23HPQAGGVEV0.94690.8673716
AFF3-HDAC5chr2100623094chr1742171202986HLA-B35:09HPQAGGVEV0.94510.9594716
AFF3-HDAC5chr2100623094chr1742171202986HLA-B51:29HPQAGGVEV0.9260.591716
AFF3-HDAC5chr2100623094chr1742171202986HLA-B51:09HPQAGGVEV0.91140.766716
AFF3-HDAC5chr2100623094chr1742171202986HLA-B55:04HPQAGGVEV0.90590.7441716
AFF3-HDAC5chr2100623094chr1742171202986HLA-B78:02HPQAGGVEV0.9040.8682716
AFF3-HDAC5chr2100623094chr1742171202986HLA-B51:13HPQAGGVEV0.89760.7355716
AFF3-HDAC5chr2100623094chr1742171202986HLA-B35:30HPQAGGVEV0.8810.7352716
AFF3-HDAC5chr2100623094chr1742171202986HLA-B35:17HPQAGGVEV0.8810.7352716
AFF3-HDAC5chr2100623094chr1742171202986HLA-B35:11HPQAGGVEV0.85540.8795716
AFF3-HDAC5chr2100623094chr1742171202986HLA-B51:14HPQAGGVEV0.84560.7092716
AFF3-HDAC5chr2100623094chr1742171202986HLA-B51:21HPQAGGVEV0.83430.7191716
AFF3-HDAC5chr2100623094chr1742171202986HLA-B67:01HPQAGGVEV0.81190.9528716
AFF3-HDAC5chr2100623094chr1742171202986HLA-B51:06HPQAGGVEV0.78740.7178716
AFF3-HDAC5chr2100623094chr1742171202986HLA-B35:24HPQAGGVEV0.5890.8821716
AFF3-HDAC5chr2100623094chr1742171202986HLA-B82:02HPQAGGVEV0.22040.7893716
AFF3-HDAC5chr2100623094chr1742171202986HLA-B35:43HPQAGGVEV0.02260.8235716
AFF3-HDAC5chr2100623094chr1742171202986HLA-B15:09QHPQAGGVEV0.94480.9327616
AFF3-HDAC5chr2100623094chr1742171202986HLA-B39:11QHPQAGGVEV0.86810.8863616

Top

Potential FusionNeoAntigen Information of AFF3-HDAC5 in HLA II

check button Multiple sequence alignments of the potential FusionNeoAntigens per fusion breakpoints. If the MSA is empty, then it means that there were predicted fusion neoantigens in this fusion breakpoint, but those predicted fusion neoantigens were not across the breakpoint, which is not fusion-specific.
AFF3-HDAC5_100623094_42171202.msa

check button Potential FusionNeoAntigen Information
* We used NetMHCIIpan v4.1 (%rank<0.5).
Fusion geneHchrHbpTgeneTchrTbpHLA IIFusionNeoAntigen peptideNeoantigen start (at BP 13)Neoantigen end (at BP 13)
AFF3-HDAC5chr2100623094chr1742171202986DRB1-1102AGGVEVKPVLPRAMP1025
AFF3-HDAC5chr2100623094chr1742171202986DRB1-1102QAGGVEVKPVLPRAM924
AFF3-HDAC5chr2100623094chr1742171202986DRB1-1102PQAGGVEVKPVLPRA823
AFF3-HDAC5chr2100623094chr1742171202986DRB1-1103AGGVEVKPVLPRAMP1025
AFF3-HDAC5chr2100623094chr1742171202986DRB1-1116AGGVEVKPVLPRAMP1025
AFF3-HDAC5chr2100623094chr1742171202986DRB1-1116QAGGVEVKPVLPRAM924
AFF3-HDAC5chr2100623094chr1742171202986DRB1-1116PQAGGVEVKPVLPRA823
AFF3-HDAC5chr2100623094chr1742171202986DRB1-1121AGGVEVKPVLPRAMP1025
AFF3-HDAC5chr2100623094chr1742171202986DRB1-1121QAGGVEVKPVLPRAM924
AFF3-HDAC5chr2100623094chr1742171202986DRB1-1121PQAGGVEVKPVLPRA823
AFF3-HDAC5chr2100623094chr1742171202986DRB1-1121GGVEVKPVLPRAMPS1126
AFF3-HDAC5chr2100623094chr1742171202986DRB1-1136AGGVEVKPVLPRAMP1025
AFF3-HDAC5chr2100623094chr1742171202986DRB1-1136QAGGVEVKPVLPRAM924
AFF3-HDAC5chr2100623094chr1742171202986DRB1-1136PQAGGVEVKPVLPRA823
AFF3-HDAC5chr2100623094chr1742171202986DRB1-1148AGGVEVKPVLPRAMP1025
AFF3-HDAC5chr2100623094chr1742171202986DRB1-1148QAGGVEVKPVLPRAM924
AFF3-HDAC5chr2100623094chr1742171202986DRB1-1148PQAGGVEVKPVLPRA823
AFF3-HDAC5chr2100623094chr1742171202986DRB1-1155AGGVEVKPVLPRAMP1025
AFF3-HDAC5chr2100623094chr1742171202986DRB1-1159AGGVEVKPVLPRAMP1025
AFF3-HDAC5chr2100623094chr1742171202986DRB1-1163AGGVEVKPVLPRAMP1025
AFF3-HDAC5chr2100623094chr1742171202986DRB1-1165AGGVEVKPVLPRAMP1025
AFF3-HDAC5chr2100623094chr1742171202986DRB1-1165QAGGVEVKPVLPRAM924
AFF3-HDAC5chr2100623094chr1742171202986DRB1-1165PQAGGVEVKPVLPRA823
AFF3-HDAC5chr2100623094chr1742171202986DRB1-1168AGGVEVKPVLPRAMP1025
AFF3-HDAC5chr2100623094chr1742171202986DRB1-1170AGGVEVKPVLPRAMP1025
AFF3-HDAC5chr2100623094chr1742171202986DRB1-1170QAGGVEVKPVLPRAM924
AFF3-HDAC5chr2100623094chr1742171202986DRB1-1170PQAGGVEVKPVLPRA823
AFF3-HDAC5chr2100623094chr1742171202986DRB1-1176AGGVEVKPVLPRAMP1025
AFF3-HDAC5chr2100623094chr1742171202986DRB1-1185AGGVEVKPVLPRAMP1025
AFF3-HDAC5chr2100623094chr1742171202986DRB1-1186AGGVEVKPVLPRAMP1025
AFF3-HDAC5chr2100623094chr1742171202986DRB1-1301AGGVEVKPVLPRAMP1025
AFF3-HDAC5chr2100623094chr1742171202986DRB1-1301QAGGVEVKPVLPRAM924
AFF3-HDAC5chr2100623094chr1742171202986DRB1-1301PQAGGVEVKPVLPRA823
AFF3-HDAC5chr2100623094chr1742171202986DRB1-1308AGGVEVKPVLPRAMP1025
AFF3-HDAC5chr2100623094chr1742171202986DRB1-1308QAGGVEVKPVLPRAM924
AFF3-HDAC5chr2100623094chr1742171202986DRB1-1308PQAGGVEVKPVLPRA823
AFF3-HDAC5chr2100623094chr1742171202986DRB1-1309AGGVEVKPVLPRAMP1025
AFF3-HDAC5chr2100623094chr1742171202986DRB1-1315AGGVEVKPVLPRAMP1025
AFF3-HDAC5chr2100623094chr1742171202986DRB1-1315QAGGVEVKPVLPRAM924
AFF3-HDAC5chr2100623094chr1742171202986DRB1-1315PQAGGVEVKPVLPRA823
AFF3-HDAC5chr2100623094chr1742171202986DRB1-1315GGVEVKPVLPRAMPS1126
AFF3-HDAC5chr2100623094chr1742171202986DRB1-1316AGGVEVKPVLPRAMP1025
AFF3-HDAC5chr2100623094chr1742171202986DRB1-1317AGGVEVKPVLPRAMP1025
AFF3-HDAC5chr2100623094chr1742171202986DRB1-1317QAGGVEVKPVLPRAM924
AFF3-HDAC5chr2100623094chr1742171202986DRB1-1317PQAGGVEVKPVLPRA823
AFF3-HDAC5chr2100623094chr1742171202986DRB1-1317GGVEVKPVLPRAMPS1126
AFF3-HDAC5chr2100623094chr1742171202986DRB1-1319AGGVEVKPVLPRAMP1025
AFF3-HDAC5chr2100623094chr1742171202986DRB1-1319QAGGVEVKPVLPRAM924
AFF3-HDAC5chr2100623094chr1742171202986DRB1-1319PQAGGVEVKPVLPRA823
AFF3-HDAC5chr2100623094chr1742171202986DRB1-1319GGVEVKPVLPRAMPS1126
AFF3-HDAC5chr2100623094chr1742171202986DRB1-1320AGGVEVKPVLPRAMP1025
AFF3-HDAC5chr2100623094chr1742171202986DRB1-1320QAGGVEVKPVLPRAM924
AFF3-HDAC5chr2100623094chr1742171202986DRB1-1320PQAGGVEVKPVLPRA823
AFF3-HDAC5chr2100623094chr1742171202986DRB1-1322AGGVEVKPVLPRAMP1025
AFF3-HDAC5chr2100623094chr1742171202986DRB1-1322QAGGVEVKPVLPRAM924
AFF3-HDAC5chr2100623094chr1742171202986DRB1-1322PQAGGVEVKPVLPRA823
AFF3-HDAC5chr2100623094chr1742171202986DRB1-1324AGGVEVKPVLPRAMP1025
AFF3-HDAC5chr2100623094chr1742171202986DRB1-1327AGGVEVKPVLPRAMP1025
AFF3-HDAC5chr2100623094chr1742171202986DRB1-1327QAGGVEVKPVLPRAM924
AFF3-HDAC5chr2100623094chr1742171202986DRB1-1327PQAGGVEVKPVLPRA823
AFF3-HDAC5chr2100623094chr1742171202986DRB1-1327GGVEVKPVLPRAMPS1126
AFF3-HDAC5chr2100623094chr1742171202986DRB1-1329AGGVEVKPVLPRAMP1025
AFF3-HDAC5chr2100623094chr1742171202986DRB1-1335AGGVEVKPVLPRAMP1025
AFF3-HDAC5chr2100623094chr1742171202986DRB1-1335QAGGVEVKPVLPRAM924
AFF3-HDAC5chr2100623094chr1742171202986DRB1-1335PQAGGVEVKPVLPRA823
AFF3-HDAC5chr2100623094chr1742171202986DRB1-1341AGGVEVKPVLPRAMP1025
AFF3-HDAC5chr2100623094chr1742171202986DRB1-1343AGGVEVKPVLPRAMP1025
AFF3-HDAC5chr2100623094chr1742171202986DRB1-1351AGGVEVKPVLPRAMP1025
AFF3-HDAC5chr2100623094chr1742171202986DRB1-1351QAGGVEVKPVLPRAM924
AFF3-HDAC5chr2100623094chr1742171202986DRB1-1351PQAGGVEVKPVLPRA823
AFF3-HDAC5chr2100623094chr1742171202986DRB1-1352AGGVEVKPVLPRAMP1025
AFF3-HDAC5chr2100623094chr1742171202986DRB1-1352QAGGVEVKPVLPRAM924
AFF3-HDAC5chr2100623094chr1742171202986DRB1-1352PQAGGVEVKPVLPRA823
AFF3-HDAC5chr2100623094chr1742171202986DRB1-1353AGGVEVKPVLPRAMP1025
AFF3-HDAC5chr2100623094chr1742171202986DRB1-1353QAGGVEVKPVLPRAM924
AFF3-HDAC5chr2100623094chr1742171202986DRB1-1353PQAGGVEVKPVLPRA823
AFF3-HDAC5chr2100623094chr1742171202986DRB1-1353GGVEVKPVLPRAMPS1126
AFF3-HDAC5chr2100623094chr1742171202986DRB1-1357AGGVEVKPVLPRAMP1025
AFF3-HDAC5chr2100623094chr1742171202986DRB1-1357QAGGVEVKPVLPRAM924
AFF3-HDAC5chr2100623094chr1742171202986DRB1-1357PQAGGVEVKPVLPRA823
AFF3-HDAC5chr2100623094chr1742171202986DRB1-1357GGVEVKPVLPRAMPS1126
AFF3-HDAC5chr2100623094chr1742171202986DRB1-1359AGGVEVKPVLPRAMP1025
AFF3-HDAC5chr2100623094chr1742171202986DRB1-1359QAGGVEVKPVLPRAM924
AFF3-HDAC5chr2100623094chr1742171202986DRB1-1359PQAGGVEVKPVLPRA823
AFF3-HDAC5chr2100623094chr1742171202986DRB1-1361AGGVEVKPVLPRAMP1025
AFF3-HDAC5chr2100623094chr1742171202986DRB1-1361QAGGVEVKPVLPRAM924
AFF3-HDAC5chr2100623094chr1742171202986DRB1-1361PQAGGVEVKPVLPRA823
AFF3-HDAC5chr2100623094chr1742171202986DRB1-1361GGVEVKPVLPRAMPS1126
AFF3-HDAC5chr2100623094chr1742171202986DRB1-1364AGGVEVKPVLPRAMP1025
AFF3-HDAC5chr2100623094chr1742171202986DRB1-1364QAGGVEVKPVLPRAM924
AFF3-HDAC5chr2100623094chr1742171202986DRB1-1364PQAGGVEVKPVLPRA823
AFF3-HDAC5chr2100623094chr1742171202986DRB1-1368AGGVEVKPVLPRAMP1025
AFF3-HDAC5chr2100623094chr1742171202986DRB1-1368QAGGVEVKPVLPRAM924
AFF3-HDAC5chr2100623094chr1742171202986DRB1-1368PQAGGVEVKPVLPRA823
AFF3-HDAC5chr2100623094chr1742171202986DRB1-1369AGGVEVKPVLPRAMP1025
AFF3-HDAC5chr2100623094chr1742171202986DRB1-1369QAGGVEVKPVLPRAM924
AFF3-HDAC5chr2100623094chr1742171202986DRB1-1369PQAGGVEVKPVLPRA823
AFF3-HDAC5chr2100623094chr1742171202986DRB1-1370AGGVEVKPVLPRAMP1025
AFF3-HDAC5chr2100623094chr1742171202986DRB1-1370QAGGVEVKPVLPRAM924
AFF3-HDAC5chr2100623094chr1742171202986DRB1-1370PQAGGVEVKPVLPRA823
AFF3-HDAC5chr2100623094chr1742171202986DRB1-1371AGGVEVKPVLPRAMP1025
AFF3-HDAC5chr2100623094chr1742171202986DRB1-1371QAGGVEVKPVLPRAM924
AFF3-HDAC5chr2100623094chr1742171202986DRB1-1371PQAGGVEVKPVLPRA823
AFF3-HDAC5chr2100623094chr1742171202986DRB1-1372AGGVEVKPVLPRAMP1025
AFF3-HDAC5chr2100623094chr1742171202986DRB1-1372QAGGVEVKPVLPRAM924
AFF3-HDAC5chr2100623094chr1742171202986DRB1-1372PQAGGVEVKPVLPRA823
AFF3-HDAC5chr2100623094chr1742171202986DRB1-1376AGGVEVKPVLPRAMP1025
AFF3-HDAC5chr2100623094chr1742171202986DRB1-1378AGGVEVKPVLPRAMP1025
AFF3-HDAC5chr2100623094chr1742171202986DRB1-1378QAGGVEVKPVLPRAM924
AFF3-HDAC5chr2100623094chr1742171202986DRB1-1378PQAGGVEVKPVLPRA823
AFF3-HDAC5chr2100623094chr1742171202986DRB1-1379AGGVEVKPVLPRAMP1025
AFF3-HDAC5chr2100623094chr1742171202986DRB1-1379QAGGVEVKPVLPRAM924
AFF3-HDAC5chr2100623094chr1742171202986DRB1-1379PQAGGVEVKPVLPRA823
AFF3-HDAC5chr2100623094chr1742171202986DRB1-1380AGGVEVKPVLPRAMP1025
AFF3-HDAC5chr2100623094chr1742171202986DRB1-1380QAGGVEVKPVLPRAM924
AFF3-HDAC5chr2100623094chr1742171202986DRB1-1380PQAGGVEVKPVLPRA823
AFF3-HDAC5chr2100623094chr1742171202986DRB1-1383AGGVEVKPVLPRAMP1025
AFF3-HDAC5chr2100623094chr1742171202986DRB1-1383QAGGVEVKPVLPRAM924
AFF3-HDAC5chr2100623094chr1742171202986DRB1-1383PQAGGVEVKPVLPRA823
AFF3-HDAC5chr2100623094chr1742171202986DRB1-1384AGGVEVKPVLPRAMP1025
AFF3-HDAC5chr2100623094chr1742171202986DRB1-1384QAGGVEVKPVLPRAM924
AFF3-HDAC5chr2100623094chr1742171202986DRB1-1384PQAGGVEVKPVLPRA823
AFF3-HDAC5chr2100623094chr1742171202986DRB1-1387AGGVEVKPVLPRAMP1025
AFF3-HDAC5chr2100623094chr1742171202986DRB1-1387QAGGVEVKPVLPRAM924
AFF3-HDAC5chr2100623094chr1742171202986DRB1-1387PQAGGVEVKPVLPRA823
AFF3-HDAC5chr2100623094chr1742171202986DRB1-1391AGGVEVKPVLPRAMP1025
AFF3-HDAC5chr2100623094chr1742171202986DRB1-1391QAGGVEVKPVLPRAM924
AFF3-HDAC5chr2100623094chr1742171202986DRB1-1391PQAGGVEVKPVLPRA823
AFF3-HDAC5chr2100623094chr1742171202986DRB1-1392AGGVEVKPVLPRAMP1025
AFF3-HDAC5chr2100623094chr1742171202986DRB1-1392QAGGVEVKPVLPRAM924
AFF3-HDAC5chr2100623094chr1742171202986DRB1-1392PQAGGVEVKPVLPRA823
AFF3-HDAC5chr2100623094chr1742171202986DRB1-1396AGGVEVKPVLPRAMP1025
AFF3-HDAC5chr2100623094chr1742171202986DRB1-1398AGGVEVKPVLPRAMP1025
AFF3-HDAC5chr2100623094chr1742171202986DRB1-1398QAGGVEVKPVLPRAM924
AFF3-HDAC5chr2100623094chr1742171202986DRB1-1403AGGVEVKPVLPRAMP1025
AFF3-HDAC5chr2100623094chr1742171202986DRB1-1406AGGVEVKPVLPRAMP1025
AFF3-HDAC5chr2100623094chr1742171202986DRB1-1412AGGVEVKPVLPRAMP1025
AFF3-HDAC5chr2100623094chr1742171202986DRB1-1412QAGGVEVKPVLPRAM924
AFF3-HDAC5chr2100623094chr1742171202986DRB1-1412PQAGGVEVKPVLPRA823
AFF3-HDAC5chr2100623094chr1742171202986DRB1-1412GGVEVKPVLPRAMPS1126
AFF3-HDAC5chr2100623094chr1742171202986DRB1-1420AGGVEVKPVLPRAMP1025
AFF3-HDAC5chr2100623094chr1742171202986DRB1-1424AGGVEVKPVLPRAMP1025
AFF3-HDAC5chr2100623094chr1742171202986DRB1-1429AGGVEVKPVLPRAMP1025
AFF3-HDAC5chr2100623094chr1742171202986DRB1-1429QAGGVEVKPVLPRAM924
AFF3-HDAC5chr2100623094chr1742171202986DRB1-1437AGGVEVKPVLPRAMP1025
AFF3-HDAC5chr2100623094chr1742171202986DRB1-1440AGGVEVKPVLPRAMP1025
AFF3-HDAC5chr2100623094chr1742171202986DRB1-1452AGGVEVKPVLPRAMP1025
AFF3-HDAC5chr2100623094chr1742171202986DRB1-1452QAGGVEVKPVLPRAM924
AFF3-HDAC5chr2100623094chr1742171202986DRB1-1477AGGVEVKPVLPRAMP1025
AFF3-HDAC5chr2100623094chr1742171202986DRB1-1481AGGVEVKPVLPRAMP1025
AFF3-HDAC5chr2100623094chr1742171202986DRB1-1483AGGVEVKPVLPRAMP1025
AFF3-HDAC5chr2100623094chr1742171202986DRB1-1484AGGVEVKPVLPRAMP1025
AFF3-HDAC5chr2100623094chr1742171202986DRB1-1489AGGVEVKPVLPRAMP1025
AFF3-HDAC5chr2100623094chr1742171202986DRB1-1498AGGVEVKPVLPRAMP1025
AFF3-HDAC5chr2100623094chr1742171202986DRB1-1498QAGGVEVKPVLPRAM924
AFF3-HDAC5chr2100623094chr1742171202986DRB4-0101GQALQVQHPQAGGVE015
AFF3-HDAC5chr2100623094chr1742171202986DRB4-0101QALQVQHPQAGGVEV116
AFF3-HDAC5chr2100623094chr1742171202986DRB4-0103GQALQVQHPQAGGVE015
AFF3-HDAC5chr2100623094chr1742171202986DRB4-0103QALQVQHPQAGGVEV116
AFF3-HDAC5chr2100623094chr1742171202986DRB4-0104GQALQVQHPQAGGVE015
AFF3-HDAC5chr2100623094chr1742171202986DRB4-0104QALQVQHPQAGGVEV116
AFF3-HDAC5chr2100623094chr1742171202986DRB4-0106GQALQVQHPQAGGVE015
AFF3-HDAC5chr2100623094chr1742171202986DRB4-0106QALQVQHPQAGGVEV116
AFF3-HDAC5chr2100623094chr1742171202986DRB4-0107GQALQVQHPQAGGVE015
AFF3-HDAC5chr2100623094chr1742171202986DRB4-0107QALQVQHPQAGGVEV116
AFF3-HDAC5chr2100623094chr1742171202986DRB4-0108GQALQVQHPQAGGVE015
AFF3-HDAC5chr2100623094chr1742171202986DRB4-0108QALQVQHPQAGGVEV116
AFF3-HDAC5chr2100623094chr1742171202986DRB5-0106AGGVEVKPVLPRAMP1025
AFF3-HDAC5chr2100623094chr1742171202986DRB5-0202AGGVEVKPVLPRAMP1025

Top

Fusion breakpoint peptide structures of AFF3-HDAC5

check button3D structures of the fusion breakpoint peptide of 14AA sequence that have potential fusion neoantigens
* The minimum length of the amino acid sequence in RoseTTAFold is 14AA. Here, we predicted the 14AA fusion protein breakpoint sequence not the fusion neoantigen peptide, which is shorter than 14 AA.
File nameBPseqHgeneTgeneHchrHbpTchrTbpAAlen
7305QHPQAGGVEVKPVLAFF3HDAC5chr2100623094chr1742171202986

Top

Filtering FusionNeoAntigens Through Checking the Interaction with HLAs in 3D of AFF3-HDAC5

check buttonVirtual screening between 25 HLAs (from PDB) and FusionNeoAntigens
* We used Glide to predict the interaction between HLAs and neoantigens.
HLA allelePDB IDFile nameBPseqDocking scoreGlide score
HLA-B14:023BVN7305QHPQAGGVEVKPVL-7.9962-8.1096
HLA-B14:023BVN7305QHPQAGGVEVKPVL-5.70842-6.74372
HLA-B52:013W397305QHPQAGGVEVKPVL-6.83737-6.95077
HLA-B52:013W397305QHPQAGGVEVKPVL-4.4836-5.5189
HLA-A11:014UQ27305QHPQAGGVEVKPVL-10.0067-10.1201
HLA-A11:014UQ27305QHPQAGGVEVKPVL-9.03915-10.0745
HLA-A24:025HGA7305QHPQAGGVEVKPVL-6.56204-6.67544
HLA-A24:025HGA7305QHPQAGGVEVKPVL-5.42271-6.45801
HLA-B44:053DX87305QHPQAGGVEVKPVL-7.85648-8.89178
HLA-B44:053DX87305QHPQAGGVEVKPVL-5.3978-5.5112
HLA-A02:016TDR7305QHPQAGGVEVKPVL-3.37154-4.40684

Top

Vaccine Design for the FusionNeoAntigens of AFF3-HDAC5

check button mRNA and peptide sequences of FusionNeoAntigens that have potential interaction with HLA-Is.
Fusion geneHchrHbpTchrTbpStart in +/-13AAEnd in +/-13AAFusionNeoAntigen peptide sequenceFusionNeoAntigen RNA sequence
AFF3-HDAC5chr2100623094chr1742171202514VQHPQAGGVTTCAGCATCCCCAAGCAGGGGGAGTGG
AFF3-HDAC5chr2100623094chr1742171202516VQHPQAGGVEVTTCAGCATCCCCAAGCAGGGGGAGTGGAGGTGA
AFF3-HDAC5chr2100623094chr1742171202616QHPQAGGVEVAGCATCCCCAAGCAGGGGGAGTGGAGGTGA
AFF3-HDAC5chr2100623094chr1742171202716HPQAGGVEVATCCCCAAGCAGGGGGAGTGGAGGTGA

check button mRNA and peptide sequences of FusionNeoAntigens that have potential interaction with HLA-IIs.
Fusion geneHchrHbpTchrTbpStart in +/-13AAEnd in +/-13AAFusionNeoAntigen peptideFusionNEoAntigen RNA sequence
AFF3-HDAC5chr2100623094chr1742171202015GQALQVQHPQAGGVEGCCAAGCTCTCCAAGTTCAGCATCCCCAAGCAGGGGGAGTGGAGG
AFF3-HDAC5chr2100623094chr1742171202116QALQVQHPQAGGVEVAAGCTCTCCAAGTTCAGCATCCCCAAGCAGGGGGAGTGGAGGTGA
AFF3-HDAC5chr2100623094chr17421712021025AGGVEVKPVLPRAMPCAGGGGGAGTGGAGGTGAAGCCGGTGCTGCCAAGAGCCATGCCCA
AFF3-HDAC5chr2100623094chr17421712021126GGVEVKPVLPRAMPSGGGGAGTGGAGGTGAAGCCGGTGCTGCCAAGAGCCATGCCCAGTT
AFF3-HDAC5chr2100623094chr1742171202823PQAGGVEVKPVLPRACCCAAGCAGGGGGAGTGGAGGTGAAGCCGGTGCTGCCAAGAGCCA
AFF3-HDAC5chr2100623094chr1742171202924QAGGVEVKPVLPRAMAAGCAGGGGGAGTGGAGGTGAAGCCGGTGCTGCCAAGAGCCATGC

Top

Information of the samples that have these potential fusion neoantigens of AFF3-HDAC5

check button These samples were reported as having these fusion breakpoints. For individual breakpoints, we checked the open reading frames considering multiple gene isoforms and chose the in-frame fusion genes only. Then, we made fusion protein sequences and predicted the fusion neoantigens. These fusion-positive samples may have these potential fusion neoantigens.
Cancer typeFusion geneHchrHbpHenstTchrTbpTenstSample
PRADAFF3-HDAC5chr2100623094ENST00000409236chr1742171202ENST00000225983TCGA-YL-A8HO-01A

Top

Potential target of CAR-T therapy development for AFF3-HDAC5

check button Predicted 3D structure. We used RoseTTAFold.

check buttonRetention analysis result of each fusion partner protein across 39 protein features of UniProt such as six molecule processing features, 13 region features, four site features, six amino acid modification features, two natural variation features, five experimental info features, and 3 secondary structure features. Here, to provide the retention of the transmembrane domain, we only show the protein feature retention information of those transmembrane features


* Minus value of BPloci means that the break point is located before the CDS.
- In-frame and retained 'Transmembrane'.
PartnerGeneHbpTbpENSTStrandBPexonTotalExonProtein feature loci*BPlociTotalLenProtein featureProtein feature note

check button Subcellular localization prediction of the transmembrane domain retained fusion proteins
* We used DeepLoc 1.0. The order of the X-axis of the barplot is as follows: Entry_ID, Localization, Type, Nucleus, Cytoplasm, Extracellular, Mitochondrion, Cell_membrane, Endoplasmic_reticulum, Plastid, Golgi.apparatus, Lysosome.Vacuole, Peroxisome. Y-axis is the output score of DeepLoc. Clicking the image will open a new tab with a large image.
HgeneHchrHbpHenstTgeneTchrTbpTenstDeepLoc result

Top

Related Drugs to AFF3-HDAC5

check button Drugs used for this fusion-positive patient.
(Manual curation of PubMed, 04-30-2022 + MyCancerGenome)
HgeneTgeneDrugSourcePMID

Top

Related Diseases to AFF3-HDAC5

check button Diseases that have this fusion gene.
(Manual curation of PubMed, 04-30-2022 + MyCancerGenome)
HgeneTgeneDiseaseSourcePMID

check button Diseases associated with fusion partners.
(DisGeNet 4.0)
PartnerGeneDisease IDDisease name# pubmedsSource
HgeneAFF3C0003873Rheumatoid Arthritis2CTD_human
HgeneAFF3C0013146Drug abuse1CTD_human
HgeneAFF3C0013170Drug habituation1CTD_human
HgeneAFF3C0013222Drug Use Disorders1CTD_human
HgeneAFF3C0029231Organic Mental Disorders, Substance-Induced1CTD_human
HgeneAFF3C0036572Seizures1GENOMICS_ENGLAND
HgeneAFF3C0038580Substance Dependence1CTD_human
HgeneAFF3C0038586Substance Use Disorders1CTD_human
HgeneAFF3C0236969Substance-Related Disorders1CTD_human
HgeneAFF3C0740858Substance abuse problem1CTD_human
HgeneAFF3C1510472Drug Dependence1CTD_human
HgeneAFF3C3714756Intellectual Disability1GENOMICS_ENGLAND
HgeneAFF3C4316881Prescription Drug Abuse1CTD_human